Factors Contributing to the Long Duration of TB Drug Clinical Development

Tuberculosis is an infection caused by Mycobacterium tuberculosis. It usually spreads from people to people by sneezing, sneezing, or speaking contaminated aerosol droplets of an infected person. It usually affects the lungs, but diseases can spread through the blood to other parts of the body. Common symptoms of tuberculosis include chronic cough, fever, and night sweats. There are various diagnostic assays available for detecting tuberculosis or M.

XDR - TB refers to TB strains that are resistant to rifampicin and isoniazid and fluoroquinolones, and three injectable TB drugs, capreomycin, kanamycin and amikacin. The Nix-TB trial is the first TB clinical trial to test a new drug combination that may be shorter and more perfect for oral and affordable treatment against XDR-TB. This combination does not require injections and tablets are much less. Research by Rockefeller's scientists hopes for a new class of powerful anti-tuberculosis weapons. Their research focuses on antibiotics that kill MTB in laboratories but are not suitable for clinical use. Fidamycin is very good at killing Mycobacterium tuberculosis cultured in the laboratory. However, when ingested, the antibiotic will be absorbed in the intestines and eventually reach the lung - but fidaxomycin can not do this

Drug-resistant tuberculosis strains occur when antibiotics do not kill all of the bacteria they target. The surviving bacteria are also resistant to certain drugs and other antibiotics. Several tuberculosis strains are resistant to the most commonly used treatments such as isoniazid and rifampicin. Some tuberculosis strains also develop resistance to antibiotics called fluoroquinolones and drugs that are not commonly used for the treatment of tuberculosis, such as injectable drugs including amikacin, kanamycin and capreomycin. These medications are more commonly used to treat infections that are resistant to drugs that are more commonly used.